April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Available Treatment Options for Relapsed/Refractory Multiple Myeloma
Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.
Trial Data Review: Selinexor, Carfilzomib, and Dexamethasone in R/R MM
October 13th 2022Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.
Racial Disparities in Presentation, Diagnosis, and Treatment of MM
October 12th 2022Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.
Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.
Maintenance Therapy in Transplant-Ineligible NDMM
Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.
Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.
Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.